Fierce Pharma Asia—Astellas’ gene therapy ding; BeiGene, Novartis’ PD-1 win; Serum Institute’s unused COVID shots
Fierce Pharma Asia—Astellas’ gene therapy ding; BeiGene, Novartis’ PD-1 win; [...]
Fierce Pharma Asia—Astellas’ gene therapy ding; BeiGene, Novartis’ PD-1 win; [...]
If Lilly’s Alzheimer’s prospect proves its merit, it’s ‘inconceivable’ CMS [...]
Amgen vows to fight $7.1B tax bill tied to Puerto [...]
Novartis confirms ‘thousands’ of layoffs loom as its global reorganization [...]
FDA expands approval of Gilead’s Veklury, providing young children their [...]
FDA plans study into how patients and physicians make prescription [...]
Roche delays Polivy’s blockbuster lymphoma filing as FDA asks for [...]
After Brexafemme approval, Scynexis touts data that could broaden the [...]
With 200M unused doses, AstraZeneca’s COVID vaccine partner Serum Institute [...]
As US launch falters, Biogen ditches Aduhelm application in Europe [...]